Patient Resources: Central Ohio Men Against Prostate Cancer

Central Ohio Men Against Prostate Cancer is a community-based non-profit organization with the goal to increase prostate cancer awareness and reduce disparities in prostate cancer among minorities and medically underserved.

Founded in 2004, the organization has hosted a number of screening events, research fundraisers and education seminars and Columbus CyberKnife is proud to have partnered with the group in the past.

Visit their website for upcoming event information, resources and inspiring patient stories.

Pictured: Columbus CyberKnife administrator Tracey Wilcox and physician services representative Amanda Brewer at a prostate health screening event hosted with the Central Ohio Men Against Prostate Cancer.


This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.

Cancer Research Update: Prostate Cancer Studies

If you’re considering stereotactic body radiation therapy for your prostate cancer diagnosis, below are a few recently published studies to help you learn more about how CyberKnife can help you. If you have any questions, please call or request more information.

— Georgetown University published the results of their study titled, “Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer” in the Radiation Oncology Journal. The team reported that SBRT for clinically localized prostate cancer was well tolerated.

— A team of researchers in New York released the results of a study of more than 300 prostate cancer patients treated with CyberKnife® technology. The study titled, “Stereotactic Body Radiotherapy for Localized Prostate Cancer: Disease Control and Quality of Life at 6 Years,” detailed that no patients experienced advanced complications from treatment and the treatment option has distinct advantages over other treatment options such as high dose rate brachytherapy.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.

Columbus CyberKnife Offers Tips for Maintaining Prostate Health

In recognition of Prostate Cancer Awareness Month, Columbus CyberKnife aims to raise awareness of the disease and educate local men on treatment options. The cancer treatment center has treated nearly 30 men for prostate cancer this year using stereotactic body radiation therapy and recently assisted with screening more than 160 men at the 9th Annual American Male Wellness Walk.

Dr. Douglas Widman, medical director of Columbus CyberKnife, recommends these steps to monitoring and maintaining one’s prostate health:

  • Talk to your doctor. One in six men will be diagnosed with prostate cancer in their lifetime. Be proactive about education on the disease and check family history. Regular visits to the doctor can help maintain overall health and detect signs and symptoms of prostate cancer.
  • Get active. Recent studies have shown that maintaining a healthy diet and exercising routinely can reduce the risk of prostate cancer by 53 percent.
  • Compare treatment options. The right prostate cancer treatment option can vary for each patient depending on a number of factors, including the size of the tumor and the patient’s lifestyle. Men should research their options and seek medical advice. (more…)

Prostate Cancer Awareness Month

This week marks the beginning of Prostate Cancer Awareness Month, which is dedicated to raising awareness, advocating for research and educating men on how to maintain their prostate health.

Here’s how you and your loved ones can participate in Prostate Cancer Awareness Month:

  • Be informed. Prostate cancer is the second most common cancer in American men with one in six men diagnosed during their lifetime. You can read more about prostate cancer and discover new resources by reading our prostate cancer blog series.
  • Get fit and fundraise. Research shows that physical activity might lower the risk of prostate cancer. Combine fitness with philanthropy to raise money for research, testing and education. Visit The Prostate Cancer Foundation’s Athletes for a Cure to find an event or organize your own.
  • Understand the diagnosis and research treatment options. Prostate cancer is a very serious disease. However, early detection will help you and your doctor decide on treatment options when necessary. Even if you or your loved one doesn’t currently have prostate cancer, don’t wait to ask questions and seek medical advice.

Learn how Columbus CyberKnife treats prostate cancer here.

ASTRO Endorses Stereotactic Body Radiation Therapy As First-Line Prostate Cancer Treatment Option

The American Society for Radiation Oncology has announced the classification of stereotactic body radiation therapy as a first-line treatment option for prostate cancer.

As a first-line treatment, SBRT can be considered a primary form of treatment for prostate cancer. The results of long-term clinical trials supporting the safety and efficacy of stereotactic body radiation in treating prostate cancer led ASTRO to announce the decision. The results of clinical studies show patient outcomes with SBRT are at least as good as other forms of radiotherapy treatments.

Columbus CyberKnife performs SBRT using CyberKnife® technology. During the procedure, the CyberKnife delivers precisely targeted, high-dose radiation beams to the prostate. CyberKnife treatment is painless and requires no cutting or sedation. Patients are treated in five or fewer sessions and experience few to no side effects.

ASTRO classifies treatments into first- and second-line options to help define coverage policies for various radiation oncology services. Read more about more ASTRO’s policy on SBRT here.

Columbus CyberKnife is pleased with this exciting milestone! For more information about the benefits of SBRT in treating prostate cancer, click here.

Research Notes: High-dose Stereotactic Body Radiotherapy Effective, Quick for Localized Prostate Cancer

In a study presented at the annual meeting of the American Society of Radiation Oncology, researchers found that men with organ-confined prostate cancer can be treated successfully with stereotactic body radiation therapy. The five-year, multi-center study evaluated low-risk, intermediate-risk and high-risk patients for up to four years following treatment. At the five-year mark, the relapse-free survival rate was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients.

Men with organ-confined prostate cancer can be treated with focused stereotactic body radiotherapy (SBRT) as outpatients in as little as five days, saving them time and money.

Centers who participated include CyberKnife Center of Tampa Bay, Tampa, Florida; Beth Israel Deaconess Medical Center, Boston; CyberKnife Centers of San Diego; San Bortolo Hospital, Vicenza, Italy; Swedish Medical Center, Seattle, WA; Georgetown University Hospital, Washington, DC, and UCLA Medical Center, Los Angeles.

To read more about the study, click here.

Additional prostate cancer news from around the web:

  • A recent study published by the Cancer Institute of New Jersey found that the definition of low-risk prostate cancer should not be the same for African American and Caucasian men. Read more.
  • The Wall Street Journal reports the results of a survey showing that the majority of people who receive cancer diagnoses choose to continue working after diagnosis and during treatment. Read more.
  • The New York Times reports that a new prostate cancer test could help supplement PSA testing to reduce false alarms and help determine more definitive diagnoses. Read more.

Prostate Cancer Series: Treatment Options

Prostate cancer is a disease specific to men and develops in the prostate, a walnut-shaped organ in a man’s lower abdomen that controls the flow of urine and semen through the reproductive system.

According to the Prostate Cancer Foundation, prostate cancer is typically a slow-growing tumor, often causing no symptoms until it reaches a more advanced stage. Once the disease begins to grow more rapidly or spreads outside the prostate, it can become a much larger health issue. This aggressive type of prostate cancer can occur at any age, though more commonly in men over 50.

Prostate cancer is suspected if men have an elevated level of a substance in the bloodstream known as prostate specific antigen or PSA. To diagnose prostate cancer, an outpatient biopsy procedure is performed. If cancer is found, biopsy findings are used to determine the patient’s risk level, such as low-risk, intermediate-risk or high-risk. The risk level assigned to a patient typically guides a doctor’s recommendations on what type of treatment, if any, should be pursued.

If facing a prostate cancer diagnosis, it is important to consider all treatment options and have a conversation with your doctor to determine the best care plan for your individual needs. Learn more about prostate cancer and how CyberKnife® treats the disease by viewing our Prostate Cancer: CyberKnife Treatment Overview below or visit the Prostate Cancer Foundation for an Introduction to Prostate Cancer Guide.

In our next post, we will highlight important prostate cancer data from the American Cancer Society’s 2013 statistics.

This post is part of a series dedicated to addressing one of the most important health issues facing men today. Check our blog for additional information about prostate cancer and the unique benefits of CyberKnife® treatment.

Prostate Cancer by the Numbers: American Cancer Society Facts and Figures

When facing a cancer diagnosis, patients should consult their doctor to learn more about the best treatment for their diagnosis. Consultation is a key part of making an informed treatment decision given the impact different forms of treatment can have on a patient’s quality of life.

There are several different treatment options available depending on the type of cancer and the size, shape and location of a tumor. Treatment options can include surgery, radiation therapy or chemotherapy, sometimes in combination.

Columbus CyberKnife offers a treatment option called stereotactic radiosurgery, an advanced form of radiation therapy that delivers high-dose radiation beams to a tumor from virtually unlimited angles. Compared with conventional radiation therapy, stereotactic radiosurgery has key differences. Though both treat tumors noninvasively, radiation dosage, duration of treatment and potential side effects can differ.

The following table provides a brief overview of stereotactic radiosurgery and conventional radiation therapy.

Stereotactic Radiosurgery

The information provided about medical conditions, treatment options, comparisons and associated risks is a very brief overview. Not all patients are CyberKnife® candidates. Consult your doctor for any diagnosis and its best treatment.

*Source: American Cancer Society.

Prostate Cancer Treatment Advancements Improve Survivorship

One in six men will face a prostate cancer diagnosis in his lifetime, totaling to 240,000 new cases this year as estimated by the American Cancer Society. Fortunately, advancements in cancer treatment have allowed nearly eight times as many men to count themselves as survivors of the pervasive disease.

September is National Prostate Cancer Awareness Month, and Columbus CyberKnife encourages men seeking prostate cancer treatment to educate themselves on the range of options available to treat the disease.

“Advancements made in prostate cancer treatment have given patients the ability to take control of their diagnosis,” said Dr. Douglas Widman, Columbus CyberKnife medical director. “Choosing which treatment approach is most appropriate for your specific case and best suits your lifestyle is pivotal not only for the long term outcome of treatment, but also your quality of life.”